Novo Nordisk Accelerates Share Buyback Program Amid Market Pressures

Novo Nordisk DK0062498333

Novo Nordisk is maintaining a steady pace in its ongoing share repurchase initiative. The pharmaceutical giant has now acquired 1.75 million of its B shares since launching the current program at the beginning of the month. This consistent activity signals the company's commitment to returning capital to shareholders according to plan, even as its stock has recently faced headwinds in the market.

Authorized to run for a 12-month period starting February 4, the complete buyback program has a total ceiling of 15 billion DKK. The current tranche, which is scheduled to conclude on May 4, permits repurchases of up to 3.8 billion DKK. All transactions are being executed in compliance with the EU Market Abuse Regulation's Safe Harbour rules.

During the most recent trading week from February 9 to 13, the company purchased 200,000 B shares on each market day. The prices paid for these shares ranged between approximately 306 and 317 DKK per share. This pattern demonstrates a methodical, daily acquisition strategy rather than sporadic large-block purchases.

Cumulative Figures and Capital Impact

The aggregate spending since the program's inception now stands at 533.8 million DKK. Based on the shares repurchased, the average price paid per B share is 305.03 DKK.

Following these transactions, Novo Nordisk now holds 19,139,799 B shares as treasury stock. This figure represents roughly 0.4% of the company's share capital. The total number of issued A and B shares, including treasury shares, amounts to 4,465,000,000.

Strategic Context and Concurrent Developments

The buyback is proceeding during a period where Novo Nordisk's share price has encountered pressure. This is largely attributed to the company's financial outlook for 2026, which projects a potential decline in both sales and operating profit by 5% to 13%. Management cited increasing pricing pressure in the United States and the expiration of patents in certain markets as primary reasons for this forecast.

According to the company, the repurchase program serves a dual purpose: to reduce the share capital and to cover obligations related to share-based incentive plans for employees. In a separate transaction linked to these incentive programs, a net transfer of 143,527 B shares from the company occurred during the week of February 9-13. This transfer was explicitly not part of the Safe Harbour buyback program.

In a related business development, Novo Nordisk is actively defending its semaglutide products. The company initiated legal proceedings against Hims & Hers at the start of the month, targeting compounded versions of its medications.

The consistent daily purchase volume provides a clear indication of Novo Nordisk's disciplined approach to executing the current 3.8 billion DKK tranche, which remains active until May 4.